

200

Attorney Docket: 24218

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Group Art Unit: 1654

ZENNER, et al.

Examiner: Kosar, A.D.

Serial Number: 09/530,693

Filing Date: July 3, 2000

Title: **APPLICATION OF VASOPRESSIN ANTAGONISTS FOR TREATING DISTURBANCES
OR ILLNESSES OF THE INNER EAR**

TRANSMITTAL LETTER

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Information Disclosure Statement;
- (2) PTO Form-1449 with 15 cited references;
- (3) Copies of 14 of the 15 cited references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.


Respectfully submitted,
NATH & ASSOCIATES PLLC

Date filed: *Aug. 11, 2005*

NATH & ASSOCIATES PLLC
1030 15th St., N.W., 6th Fl.,
Washington, D.C. 20005-1503
(202) 775-8383

GMN/TH/1e (IDS)

By:



Gary M. Nath
Reg No. 26,965
Tanya E. Harkins
Reg. No. 52,993
Customer No. 20529



Attorney Docket: 24218

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Group Art Unit: 1654

ZENNER, et al.

Examiner: Kosar, A.D.

Serial Number: 09/530,693

Filing Date: July 3, 2000

Title: **APPLICATION OF VASOPRESSIN ANTAGONISTS FOR TREATING
DISTURBANCES OR ILLNESSES OF THE INNER EAR**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

- [XXX] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.
The enclosed statement is accompanied by [check one]:
[] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
[] ii. a check in the amount required by 37 C.F.R. 1.17(p).
- [] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.
[] Certification report(e) below; and
[] a check in the amount as required by 1.17(p).
- [] d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

[] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[XXX] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[XXX] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or

[XXX] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and

return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC


Date filed: *Aug. 11, 2005*

NATH & ASSOCIATES PLLC
1030 15th St., N.W., 6th Fl.,
Washington, D.C. 20005-1503
(202) 775-8383

GMN/TH/le (IDS)

By: 

Gary M. Nath
Reg. No. 26,965
Tanya E. Harkins
Reg. No. 52,993
Customer No. 20529



FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket:
24218

Serial Number:
09/530,693

Inventor:
ZENNER, et al

Filing Date:
July 3, 2000

Group Art Unit:
1654

Examiner:
Kosar, A.D.

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
A1	6,211,242 B1 (corresponds to WO95/29152)	3 Apr. 2001	Setoi et al.			30 Jan. 1998

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub-Class	Translation
A2	91/05549 A1	2 May 1991	WO			N/A
A3	96/33723 A2	31 Oct. 1996	WO			N/A
A4	95/29152 A1	2 Nov. 1995	WO			N/A
A5	96/41795 A1	27 Dec. 1996	WO			N/A
A6	97/15556 A1	1 May 1997	WO			Abstract
A7	0 620 216 B1	08 Jan. 2003	EP			N/A

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

A8	Mori, N., et al., "The Effect of Arginine-vasopressin and its Analogues upon the Endocochlear Potential in the Guinea Pig", <u>Acta Otolaryngol (Stockh)</u> , vol. 107, pgs. 80-84, (1989).
A9	Yamamura, Y., et al., "Characterization of a novel aquarectic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V ₂ receptor antagonist", <u>Br. J. Pharmacol.</u> , vol. 105, pgs. 787-791, (1992).
A10	"English Translation of Exhibit 1: Partial Translation of Equilibrium Research", <u>Japan Society of Equilibrium Research</u> , vol. 56, no. 2, (1997).
A11	Kitano, H., et al., "Vasopressin and oxytocin receptor mRNAs are expressed in the rat inner ear", <u>NeuroReport</u> , vol. 8, pgs. 2289-2292, (1997).
A12	"Affidavit of Masanori Ishii for Equilibrium Research", <u>Japan Society of Equilibrium Research</u> , vol. 56, no.2, pgs. 124-125, (1997).
A13	"Partial Translation of Practica Oto-Rhino-Laryngologica: Serum Antidiuretic Hormone (ADH) Levels in Patients with Vertigo and/or Deafness", <u>Practica Oto-Rhino-Laryngologica</u> , vol. 86, no. 1, pgs. 27-33, (1993).
A14	Takeda, T., et al., "Antidiuretic Hormone (ADH) and Endolymphatic Hydrops", <u>Acta Otolaryngol (Stockh)</u> , Supple vol. 519, pgs. 219-222, (1995).
A15	Serradeil-Le Gal, C., et al., "Characterization of SR 121463A, a Highly Potent and Selective, Orally Active Vasopressin V ₂ Receptor Antagonist", <u>J. Clin. Invest.</u> , vol. 98, no. 12, pgs. 2729-2738, (1996).

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.